Leucovorin

Generic Name
Leucovorin
Brand Names
EnBrace HR, EnLyte, Lederle Leucovorin
Drug Type
Small Molecule
Chemical Formula
C20H23N7O7
CAS Number
58-05-9
Unique Ingredient Identifier
Q573I9DVLP
Background

Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication

For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions
Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
Associated Therapies
-

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

First Posted Date
2023-10-30
Last Posted Date
2024-12-17
Lead Sponsor
AbbVie
Target Recruit Count
206
Registration Number
NCT06107413
Locations
🇧🇪

Universitair Ziekenhuis Leuven /ID# 257079, Leuven, Vlaams-Brabant, Belgium

🇺🇸

Highlands Oncology Group, PA /ID# 259424, Springdale, Arkansas, United States

🇺🇸

City of Hope National Medical Center /ID# 257576, Duarte, California, United States

and more 32 locations

Folinic Acid for Prevention of Pemetrexed-induced Toxicity

Phase 4
Recruiting
Conditions
Interventions
First Posted Date
2023-08-24
Last Posted Date
2023-08-24
Lead Sponsor
Amphia Hospital
Target Recruit Count
50
Registration Number
NCT06010277
Locations
🇳🇱

Amphia Hospital, Breda, Noord Brabant, Netherlands

🇳🇱

Albert Schweitzer Hospital, Dordrecht, Zuid Holland, Netherlands

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

First Posted Date
2023-07-14
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
66
Registration Number
NCT05945823
Locations
🇺🇸

University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States

🇺🇸

Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States

🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 19 locations

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

First Posted Date
2023-06-06
Last Posted Date
2024-12-05
Lead Sponsor
Arcus Biosciences, Inc.
Target Recruit Count
87
Registration Number
NCT05891171
Locations
🇺🇸

Mayo Arizona, Phoenix, Arizona, United States

🇺🇸

Mayo Florida, Jacksonville, Florida, United States

🇺🇸

Affinity Health Hope and Healing Cancer Services, LLC, Hinsdale, Illinois, United States

and more 11 locations

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

First Posted Date
2023-05-17
Last Posted Date
2024-11-05
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
408
Registration Number
NCT05863195
Locations
🇺🇸

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States

🇺🇸

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

🇺🇸

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States

and more 36 locations

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

First Posted Date
2023-05-06
Last Posted Date
2024-02-09
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
155
Registration Number
NCT05843188
Locations
🇨🇦

Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada

🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

First Posted Date
2023-02-14
Last Posted Date
2024-03-04
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
194
Registration Number
NCT05727163
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

First Posted Date
2023-02-06
Last Posted Date
2023-06-23
Lead Sponsor
NuCana plc
Target Recruit Count
91
Registration Number
NCT05714553
Locations
🇬🇧

The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

🇬🇧

Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

🇬🇧

Guy's and St Thomas NHS Foundation Trust, London, United Kingdom

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath